ATE92531T1 - Rekombinante herpes simplex-viren, vakzine und verfahren. - Google Patents

Rekombinante herpes simplex-viren, vakzine und verfahren.

Info

Publication number
ATE92531T1
ATE92531T1 AT87303512T AT87303512T ATE92531T1 AT E92531 T1 ATE92531 T1 AT E92531T1 AT 87303512 T AT87303512 T AT 87303512T AT 87303512 T AT87303512 T AT 87303512T AT E92531 T1 ATE92531 T1 AT E92531T1
Authority
AT
Austria
Prior art keywords
vaccines
methods
hsv
viruses
herpes simplex
Prior art date
Application number
AT87303512T
Other languages
English (en)
Inventor
Bernard Roizman
Original Assignee
Arch Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Dev Corp filed Critical Arch Dev Corp
Application granted granted Critical
Publication of ATE92531T1 publication Critical patent/ATE92531T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT87303512T 1986-04-25 1987-04-22 Rekombinante herpes simplex-viren, vakzine und verfahren. ATE92531T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/856,052 US4859587A (en) 1984-06-04 1986-04-25 Recombinant herpes simplex viruses, vaccines and methods
EP87303512A EP0243155B1 (de) 1986-04-25 1987-04-22 Rekombinante Herpes simplex-Viren, Vakzine und Verfahren

Publications (1)

Publication Number Publication Date
ATE92531T1 true ATE92531T1 (de) 1993-08-15

Family

ID=25322756

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87303512T ATE92531T1 (de) 1986-04-25 1987-04-22 Rekombinante herpes simplex-viren, vakzine und verfahren.

Country Status (9)

Country Link
US (1) US4859587A (de)
EP (1) EP0243155B1 (de)
JP (1) JPH084497B2 (de)
AT (1) ATE92531T1 (de)
AU (1) AU585126B2 (de)
CA (1) CA1305081C (de)
DE (1) DE3786824T2 (de)
ES (1) ES2059370T3 (de)
ZA (1) ZA87818B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
US5965138A (en) * 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
IL86180A (en) * 1987-05-04 1992-08-18 Merck & Co Inc Stable lyophilized live herpes virus vaccine and such a vaccine combined with other virus vaccines
US5633152A (en) * 1988-06-24 1997-05-27 Carnegie Institution Of Washington Method of controlling viral growth
GB8918616D0 (en) * 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
ES2070997T3 (es) * 1989-12-04 1995-06-16 Akzo Nobel Nv Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
JP3005292B2 (ja) * 1990-08-02 2000-01-31 カイロン コーポレイション 単純ヘルペスウィルスのｖｐ１６のワクチン
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5849572A (en) * 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
US5849571A (en) * 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
GB9102126D0 (en) * 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
US6040169A (en) 1991-01-31 2000-03-21 Medical Research Council Herpes simplex virus-1 deletion variants and vaccines thereof
WO1993004169A1 (en) * 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5672349A (en) * 1992-02-03 1997-09-30 Cedars Sinai Medical Center Process for the expression of herpes simplex virus type 1 glycoprotein I and methods of use
US5955088A (en) * 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5679348A (en) * 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
CA2090295A1 (en) * 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
US6193984B1 (en) 1992-02-03 2001-02-27 Cedars-Sinai Medical Center Pharmaceutical composition of herpes simplex virus typ-1 (HSV-1) glycoproteins
US6022726A (en) * 1992-02-03 2000-02-08 Palese; Peter Genetically engineered attenuated viruses
CA2132976C (en) * 1992-03-31 2003-12-30 Bernard Roizman Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis)
US6316243B1 (en) 1992-04-14 2001-11-13 Peter Palese Genetically engineered attenuated double-stranded RNA viruses
US6183753B1 (en) * 1994-08-09 2001-02-06 Schering-Plough Veterinary Corp. Recombinant chimeric virus and uses thereof
TW289731B (de) * 1992-07-09 1996-11-01 Akzo Nv
DE69332501T3 (de) * 1992-07-31 2009-03-26 The President And Fellows Of Harvard College, Cambridge Herpesvirus impfstoffe
US7223411B1 (en) 1992-07-31 2007-05-29 Dana-Farber Cancer Institute Herpesvirus replication defective mutants
DK0675962T3 (da) * 1992-12-23 2003-04-07 Arch Dev Corp Syntetiske herpessimplexviruspromotore
CA2158935A1 (en) * 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
US5763217A (en) * 1993-11-10 1998-06-09 University Of British Columbia Method of using, process of preparing and composition comprising recombinant herpesvirus vectors
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
FR2728795B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
KR100408817B1 (ko) * 1995-07-28 2004-02-25 주식회사 엘지생명과학 헤르페스심플렉스바이러스의당단백질을대량발현시키는동물세포주
US5834216A (en) * 1995-09-06 1998-11-10 Arch Development Corporation Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis)
AU1550797A (en) * 1996-01-25 1997-08-20 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
DE69838483T2 (de) 1997-10-14 2008-07-03 Darwin Molecular Corp. Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
US6399354B1 (en) 1998-07-31 2002-06-04 President And Fellows Of Harvard College Replication-competent virus expressing a detectable fusion protein
JP2002522451A (ja) 1998-08-07 2002-07-23 ユニバーシティ オブ ワシントン 免疫学的単純ヘルペスウイルス抗原とその使用法
EP1141338A4 (de) * 1998-12-31 2002-09-25 Arch Dev Corp Rekombinantes herpes simplex virus zur behandlung von neoplastischen erkrankungen
EP1695714B1 (de) * 1999-02-05 2008-07-30 Arch Development Corporation Genetisch manipulierte Herpesviren zur Behandlung von Tumoren
US6774119B1 (en) 1999-04-26 2004-08-10 Cedars-Sinai Medical Center Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
ES2286029T3 (es) 1999-07-07 2007-12-01 Zymogenetics Inc Receptor de citocina humano.
US6413518B1 (en) 1999-09-30 2002-07-02 University Of Washington Immunologically significant herpes simplex virus antigens and methods for identifying and using same
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6516246B2 (en) * 2000-09-11 2003-02-04 Mimicking Man Manually, Inc. Method and system for determining native neurological dominant hemisphere
US6846670B2 (en) 2000-11-28 2005-01-25 The University Of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
KR100976743B1 (ko) 2001-05-24 2010-08-19 지모제넥틱스, 인코포레이티드 Ｔａｃｉ-면역글로불린 융합 단백질
US6814969B2 (en) 2001-07-31 2004-11-09 University Of Washington Immunologically significant herpes simplex virus antigens and methods for using same
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
RU2225223C1 (ru) * 2002-06-14 2004-03-10 Закрытое акционерное общество Фирма "ВИТАФАРМА" Лиофилизированная антигерпетическая вакцина
DK2011510T3 (da) 2002-07-18 2011-03-28 Univ Washington Farmaceutiske sammensætninger indeholdende immunologisk aktive Herpes simplex-virus(HSV) proteinfragmenter
EP2484687A3 (de) 2003-08-08 2012-11-14 Life Technologies Corporation Verfahren und Zusammensetzungen zum nahtlosen Klonieren von Nukleinsäuremolekülen
ATE469984T1 (de) 2003-12-01 2010-06-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
WO2006002394A2 (en) * 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US20100008944A1 (en) * 2005-07-29 2010-01-14 President And Fellows Of Harvard College Herpes simplex virus mutant and uses therefore
US8460674B2 (en) * 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
EP2413950A4 (de) 2009-04-03 2013-05-01 Univ Washington Antigenes hsv-2-peptid und verwendungsverfahren dafür
DK2751279T3 (da) 2011-08-31 2017-11-20 St Jude Children's Res Hospital Fremgangsmåder og sammensætninger til påvisning af niveauet af lysosomal exocytose-aktivitet og fremgangsmåder til anvendelse
KR20150023287A (ko) 2012-04-24 2015-03-05 더 유니버시티 오브 마이애미 침습성 및 다중약물 내성 병원체에 대한 퍼포린 2 방어
AU2014331938A1 (en) 2013-10-09 2016-04-28 University Of Miami Perforin-2 activators and inhibitors as drug targets for infectious disease and gut inflammation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
EP0074808A3 (de) * 1981-09-16 1984-07-04 University Patents, Inc. Rekombinantes Verfahren und Materialien
US4554159A (en) * 1981-11-12 1985-11-19 Institute Merieux Vaccine and method of immunizing against herpes simplex virus (types 1 and 2)
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
GB8305323D0 (en) * 1983-02-25 1983-03-30 Baylor College Medicine Infectious bovine rhinotracheitis vaccine
EP0133063B1 (de) * 1983-06-23 1987-01-07 Stanley Dr. Person Immunologisch reaktive nicht-glycosilierte Aminosäureketten von Glycoprotein-B des Herpes-Virus Typ 1 und Typ 2
NL8303501A (nl) * 1983-10-12 1985-05-01 Centraal Diergeneeskundig Inst Deletiemutant van een herpesvirus en vaccin, dat dit virus bevat.
CA1282721C (en) * 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
EP0256092B1 (de) * 1986-01-27 1998-04-08 Syntro Corporation Abgeschwächte herpesviren, herpesviren, die eine für aminosäuresequenzen kodierende fremd-dns enthalten, sowie impfstoffe, die diese enthalten

Also Published As

Publication number Publication date
CA1305081C (en) 1992-07-14
EP0243155B1 (de) 1993-08-04
EP0243155A3 (en) 1989-07-26
ES2059370T3 (es) 1994-11-16
DE3786824D1 (de) 1993-09-09
US4859587A (en) 1989-08-22
JPH084497B2 (ja) 1996-01-24
DE3786824T2 (de) 1994-01-20
AU585126B2 (en) 1989-06-08
ZA87818B (en) 1987-12-30
JPS62257385A (ja) 1987-11-09
EP0243155A2 (de) 1987-10-28
AU6861487A (en) 1987-10-29

Similar Documents

Publication Publication Date Title
ATE92531T1 (de) Rekombinante herpes simplex-viren, vakzine und verfahren.
PH25776A (en) Pseudorabies virus mutants incapable of producing glycoprotein x
EP0500917A4 (en) Recombinant herpes simplex viruses vaccines and methods
MX9700833A (es) Virus de herpes recombinante de pavo y usos del mismo.
AU6489986A (en) Thymidine kinase deletion mutants of bovine herpersvirus-1, vaccines against infectious bovine rhinotracheitis containing same and methods for the production and use of same
EP0232798A3 (de) Pseudorabies-Virus-Mutanten, diese enthaltende Vakzine, Verfahren zu deren Herstellung sowie Methoden für deren Anwendung
UA40571C2 (uk) Мутант коров'ячого вірусу герпесу типу 1 (bhv-1), композиція вакцини для вакцинації тварин для захисту їх від bhv-1, композиція вакцини для вакцинації тварин для захисту їх від патогена
EP0261940A3 (de) Pseudorabies-Impfstoffe und DNS-Vektoren zur Rekombination mit Poxviren
EP0507179A3 (en) Equine herpes viruses (ehv) containing foreign dna, process for their preparation and their use as vaccines
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
AU4334193A (en) Infectious bovine rhinotracheitis virus mutants and vaccines
GR3007856T3 (de)
DK0606452T3 (da) Vektorvacciner fra rekombinant katteherpesvirus
ATE244308T1 (de) Rekombitante, equine herpesviren
NZ220645A (en) Modified varicella-zoster virus and its cultivation
EA200100720A1 (ru) Вирусная вакцина на основе делеционного вируса герпеса крупного рогатого скота типа 1 (bhv-1)
ES2132330T3 (es) Vacuna para la proteccion de caballos frente a la infeccion por el virus del herpes equino.
EP0668356A3 (de) Rekombinante, infektöse Rinder-Rhinotracheitis-Mutante, Methode zu deren Herstellung, und Vakzine dieselbige enthaltend

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time